

Special Issue

10th Anniversary of *Biomedicines*—Advances in Tendon and Bone Regeneration

Message from the Guest Editors

Injuries and degeneration of musculoskeletal tissues are generally not life-threatening diseases, but the main causes of pain, occupational disability and reduced quality of life are associated with high socio-economic costs. Therefore, elucidation of the underlying mechanisms of tissue degeneration and the development of innovative and transferable therapies to improve tissue regeneration are of great importance. This Special Issue is dedicated to the latest developments in the field of musculoskeletal degeneration and regeneration, with a focus on tendons and bone tissue. It will cover studies on the development of new preclinical models and detailed analyses of the underlying processes of tissue degeneration. The latest developments to improve musculoskeletal tissue regeneration will also be presented. We look forward to the submission of high-quality manuscripts on the topics mentioned and look forward to a very exciting Special Issue.

Guest Editors

Prof. Dr. Andreas Traweger

Institute of Tendon and Bone Regeneration, Spinal Cord Injury & Tissue Regeneration Center Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria

Prof. Dr. Britt Wildemann

Experimental Trauma Surgery, Universitätsklinikum Jena, Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Am Klinikum 1, 07747 Jena, Germany

Deadline for manuscript submissions

closed (31 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106853

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).